Trial Profile
Dose-finding study of HP-3000 in patients with idiopathic restless legs syndrome.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2017
Price :
$35
*
At a glance
- Drugs Ropinirole (Primary)
- Indications Restless legs syndrome
- Focus Adverse reactions; Therapeutic Use
- Sponsors Hisamitsu Pharmaceutical
- 02 Feb 2015 New trial record
- 23 Oct 2014 Status changed from recruiting to completed, as reported in a Hisamitsu Pharmaceutical media release.